2018 Reflux Esophagitis/GERD Drug Development- Pipeline Analysis Report

May 2018 | | ID: 25C6D0B1D84EN
VPAResearch

Abstracts

With an estimated 25 million people being affected by Reflux Esophagitis/GERD in the US, it is considered as one of the most common GI Disorders. GERD causes stomach contents regurgitate into the esophagus, causing damage to esophagus.

Around 30 companies and universities are focusing on developing treatment options for Reflux Esophagitis/GERD.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Reflux Esophagitis/GERD pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Reflux Esophagitis/GERD pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Reflux Esophagitis/GERD pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 REFLUX ESOPHAGITIS/GERD PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview
2.2 Reflux Esophagitis/GERD Pipeline Snapshot
2.3 Reflux Esophagitis/GERD Pipeline by Phase
2.4 Reflux Esophagitis/GERD Pipeline by Company
2.5 Reflux Esophagitis/GERD Pipeline by Mechanism of Action

3 REFLUX ESOPHAGITIS/GERD- COMPANY WISE PIPELINE ANALYSIS

Cancer Advances Inc
CJ HealthCare
Daewoong Pharmaceutical Co
Effexus Pharmaceutical
Eisai Co Ltd
Il-Yang Pharm.Co.,Ltd
Ironwood Pharmaceuticals
Jeil Pharmaceutical Co Ltd
Jiangsu Aosaikang Pharmaceutical
Mitsubishi Pharma Corporation
New Haven Pharmaceuticals
Pfizer
RaQualia Pharma Inc
Renexxion LLC
Rottapharm
Takeda Pharmaceutical Co
Trio Medicines Ltd
Yooyoung Pharm Co Ltd
Yuyu Pharma Inc

4 REFLUX ESOPHAGITIS/GERD R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN REFLUX ESOPHAGITIS/GERD PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Reflux Esophagitis/GERD Pipeline by Phase, H1- 2018
Figure 2: Reflux Esophagitis/GERD Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Reflux Esophagitis/GERD Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

List Of Tables

LIST OF TABLES

Table 1: Reflux Esophagitis/GERD Pipeline by Phase, H1- 2018
Table 2: Reflux Esophagitis/GERD Pipeline by Companies, H1- 2018
Table 3: Reflux Esophagitis/GERD Pipeline by Mechanism of Action, H1- 2018
Table 4: Cancer Advances Inc Reflux Esophagitis/GERD Pipeline, May 2018
Table 5: CJ HealthCare Reflux Esophagitis/GERD Pipeline, May 2018
Table 6: Daewoong Pharmaceutical Co Reflux Esophagitis/GERD Pipeline, May 2018
Table 7: Effexus Pharmaceutical Reflux Esophagitis/GERD Pipeline, May 2018
Table 8: Eisai Co Ltd Reflux Esophagitis/GERD Pipeline, May 2018
Table 9: Eisai Co Ltd Reflux Esophagitis/GERD Pipeline, May 2018
Table 10: Il-Yang Pharm.Co.,Ltd Reflux Esophagitis/GERD Pipeline, May 2018
Table 11: Ironwood Pharmaceuticals Reflux Esophagitis/GERD Pipeline, May 2018
Table 12: Jeil Pharmaceutical Co Ltd Reflux Esophagitis/GERD Pipeline, May 2018
Table 13: Jiangsu Aosaikang Pharmaceutical Reflux Esophagitis/GERD Pipeline, May 2018
Table 14: Mitsubishi Pharma Corporation Reflux Esophagitis/GERD Pipeline, May 2018
Table 15: New Haven Pharmaceuticals Reflux Esophagitis/GERD Pipeline, May 2018
Table 16: Pfizer Reflux Esophagitis/GERD Pipeline, May 2018
Table 17: RaQualia Pharma Inc Reflux Esophagitis/GERD Pipeline, May 2018
Table 18: Renexxion LLC Reflux Esophagitis/GERD Pipeline, May 2018
Table 19: Rottapharm Reflux Esophagitis/GERD Pipeline, May 2018
Table 20: Takeda Pharmaceutical Co Reflux Esophagitis/GERD Pipeline, May 2018
Table 21: Trio Medicines Ltd Reflux Esophagitis/GERD Pipeline, May 2018
Table 22: Yooyoung Pharm Co Ltd Reflux Esophagitis/GERD Pipeline, May 2018